Which XPRIZE Healthspan Teams Look Strongest Today?

EverLife | August 26, 2026

Educational research only, not investment or medical advice. Modeled scenarios are not forecasts or promised returns. Read the full disclosures.

Disclosure: EverLife and the author held no position in, and received no compensation from, any company or team named in this report as of the August 20, 2026 source-lock date.

The two highest-scoring XPRIZE teams finished close scientifically, but neither qualifies for EverLife's Research Tracker today.

That sounds like a close contest between similar companies. It is not.

One leader is testing living cells from young donors and has controlled human evidence connected to physical function. The other is built around mitochondrial biology and has a medicine already approved for a rare disease.

One leads because of what has been measured in people. The other leads because its drug platform and biological pathway are more mature than most longevity programs.

A third team leads a different category: repeated lifespan evidence in normal mammals. Another offers an approach that may be easier for people to access but is harder to study cleanly.

There is therefore no honest single answer to “Which team is best?”

The useful questions are more precise.

Which has the strongest evidence in people? Which has the strongest connection to lifespan biology? Which has the most mature path toward a regulated medicine? And which company has enough ownership, financing, and control to reach the next test?

The leader changes when the question changes.

That is why the ranking begins with evidence rather than excitement.

The complete EverLife framework contains 25 gates. But most of the ranking can be understood by starting with five plain questions.

A change in a mouse, a cell, or a blood marker can be interesting. A meaningful improvement in a controlled human study is much harder to dismiss.

I want to know whether people moved better, thought more clearly, recovered faster, or showed a stronger response to illness.

Small studies can look impressive by accident. So can studies without a placebo group.

Randomization, blinding, enough participants, and clearly chosen outcomes make it harder for hope or selective reporting to create the result.

This does not guarantee the answer is correct. It makes the answer more believable.

Even excellent science can stop if a company runs out of money.

Clinical trials, manufacturing, regulatory work, and specialized staff are expensive. A company needs enough capital or a strong partner to reach the milestone that could prove its idea.

A promising university discovery is not automatically a valuable company asset.

We need to know who owns the patents, who controls the drug, and whether the company has the commercial rights it needs.

Every research thesis should have a clear next test.

If we cannot say what would make the idea stronger or weaker, we are following a story rather than evaluating evidence.

EverLife scores each team from 1 to 5 across the same 25 questions.

A higher score means more of the important pieces can be verified: human evidence, leadership, financing, ownership, manufacturing, regulatory progress, and a clear next milestone.

It does not mean a company is guaranteed to succeed. It does not predict investment return. It does not mean shares are available.

Think of the score as a measure of how ready the opportunity is for serious research. Classification adds a second test: whether the present ownership-adjusted value leaves enough room for the risk. EverLife requires a credible 10x win case for Scout and 15x for Tracker. Those are screening hurdles, not forecasts.

A score near 4 means there is meaningful evidence and a visible development path, but important risks remain. A score near 3 means the idea deserves attention while major proof is still missing.

The top two teams finished close on the scientific and company evidence.

Yet they are not similar.

One is a public company using living cells from young donors. The other has a mitochondrial drug that has already reached FDA approval for a rare disease.

The next two take very different paths again: one targets the protein responsible for a rare premature-aging condition, and one combines existing medicines and lifestyle support.

This is useful because it shows how early the field remains. We are not choosing between four versions of the same treatment. We are watching four different ideas about what part of aging matters most.

I have kept the explanation above open so any reader can understand how I approach the ranking.

The member section below contains all ten scores, followed by a plain-English explanation of the four strongest research candidates. For each one, I explain what is genuinely encouraging, what could matter to an ordinary person, what the valuation would need to support, and what evidence is still missing.

The public finalist list tells us who is competing. The member research tells us which claims currently deserve the most confidence, where the evidence becomes thin, and what result could change the ranking. Continue below to see the full field through that lens./